Thomas Xavier, Troncy Jacques
Leukemia Unit, Hematology Dept., Edouard Herriot Hospital, Lyon, France; Outpatient Care Unit, Hematology Dept., Edouard Herriot Hospital, Lyon, France.
Adler Mus Bull. 2009 Jun;35(1):3-13.
Arsenicals have been used since ancient Greek and Roman civilizations and in the Far East as part of traditional Chinese medicine. In Western countries, they became a therapeutic mainstay for various ailments and malignancies in the 19th and early 20th centuries. Fowler's potassium bicarbonate-based solution of arsenic trioxide (As2O3)solution was the main treatment of chronic myeloid leukaemia until the 1930s. After a decline in the use of arsenic during the mid-20th century, arsenic trioxide was reintroduced as an anticancer agent after reports emerged from China of the success of an arsenic trioxide-containing herbal mixture for the treatment of acute promyelocytic leukaemia. Arsenic trioxide was first purified and used in controlled studies in China in the 1970s.Subsequently, randomised clinical trials performed in the United States led to FDA approval of arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukaemia.
自古希腊和罗马文明时期起,砷剂就已被使用,在远东地区,它还是传统中药的一部分。在西方国家,19世纪和20世纪初,砷剂成为治疗各种疾病和恶性肿瘤的主要手段。直到20世纪30年代,基于福勒氏溶液的碳酸氢钾三氧化二砷(As2O3)溶液一直是慢性粒细胞白血病的主要治疗方法。在20世纪中叶砷剂的使用减少之后,在中国有报告称含三氧化二砷的草药混合物成功治疗急性早幼粒细胞白血病后,三氧化二砷作为一种抗癌药物被重新引入。20世纪70年代,三氧化二砷在中国首次被提纯并用于对照研究。随后,在美国进行的随机临床试验导致美国食品药品监督管理局(FDA)批准三氧化二砷用于治疗复发或难治性急性早幼粒细胞白血病患者。